explore -WSS

explore

author：hotspot 2025-09-29 09:29:33 - browse：8

A screen at the New York Stock Exchange last November. Michael M. Santiago/Getty Images

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline.

The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.) It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030.

That matters because small molecules are more vulnerable to generic competition and the Medicare price negotiation introduced by the IRA. Suneet Varma, the commercial president of Pfizer’s oncology unit, said “this planned shift to biologics is expected to support the accelerated growth in both the top and bottom line,” referring to the revenue and profit lines of a balance sheet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： How to use technology to prevent future drug shortages

focus

WSS

EU fines Illumina $475 million over Grail acquisition

South Korea throws huge K

Superbugs, antibiotic resistance get scrutiny in congress

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

Watch the official trailer for 'Ahsoka' series

Drastic changes should bring profitability, startup health insurers say

entertainment

explore

entertainment

How to save PrEP access — and even expand it

Emergent cuts jobs, executive role in business shake

How one medical school became remarkably diverse

China sends large group of warplanes, navy ships towards Taiwan in forceful display

State Dept. review finds Biden bears some blame for Afghanistan failures

Wegovy’s successful heart trial raises vital question about weight loss

ChatGPT in medicine: STAT answers readers' burning questions

Drastic changes should bring profitability, startup health insurers say

Medicare details structure of new drug price negotiation program

NIH trials fail to test meaningful long Covid therapies, experts say

hotspot

Grail's uphill battle for Medicare to cover its cancer screening test

Wegovy’s successful heart trial raises vital question about weight loss

France's anti

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Emergent cuts jobs, executive role in business shake

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

focus

explore

entertainment

entertainment